Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Basiliximab use and early graft dysfunction after liver transplantation: an overlap-weighted multicenter study.

Created on 06 Nov 2026

Authors

Zeying Zhao, Yixian Huang, Zhaoyi Wu, Xixi Luo, Rui Liao, Chengcheng Zhang, Wei Liu, Na Jiang, Yanjiao Ou, Leida Zhang, Mengshi Yi

Published in

Clinics and research in hepatology and gastroenterology. Pages 102966. Nov 05, 2026. Epub Nov 05, 2026.

Abstract

Basiliximab has been associated with a reduced risk of acute cellular rejection, infection and renal failure in liver transplantation. However, its association with early graft dysfunction (EAD) and EAD-related outcomes remains unclear.
A multicenter retrospective cohort was enrolled. Association of basiliximab use with EAD, and EAD-related outcomes (prolonged ICU stay and peri-operative mortality) were evaluated. The treatment effects were estimated using overlap weighting method based on outcome-specific propensity score models incorporating recipient, donor and peri-operative characteristics. Sensitivity analysis was performed after excluding centers with highly imbalanced basiliximab use.
Of 903 eligible recipients, 393 (43.5%) received basiliximab induction. Overlap weighting achieved excellent covariate balance (nearly all absolute standardized mean differences < 0.03). After weighting, EAD incidence was 7.8 percentage points lower with basiliximab (23.3% vs. 31.1%); overlap-weighted logistic regression showed that basiliximab use was associated with significantly lower odds of EAD (OR, 0.67; 95% CI, 0.48-0.94; p = 0.02). No significant associations were observed with prolonged ICU stay or peri-operative mortality, and findings remained robust in sensitivity analyses.
Basiliximab induction was associated with lower odds of EAD after liver transplantation; however, as confounding by indication cannot be excluded in this observational design, validation in larger prospective studies is warranted.

PMID:
42988354
Bibliographic data and abstract were imported from PubMed on 06 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 11
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement